PET/CT evaluation of prostate cancer patients with Al18F-PSMA-HBED-CC: a head-to-head comparison with 68Ga-PSMA-HBED-CC.

1499Objectives: PSMA-targeting PET tracers have become available for imaging due to the over expression of PSMA in prostate cancer (PC) lesions. 68Ga-PSMA-HBED-CC (68Ga-PSMA-611, ABX) PET/CT represents a clinically relevant and commonly used technique for the evaluation of these patients. 68Ga labeled compounds are produced with generators providing limited activity per synthesis (1 to 4 patients per batch). 18F-labelled tracers, like Al18F-PSMA-HBED-CC (Al18F-PSMA-611, ABX), can be produced in larger scale with a lower positron energy that potentially offers higher image quality as well as the possibility to acquire late images. To test this hypothesis, we compared on a head-to-head basis the image quality and detection performance of both radiopharmaceuticals in a sample of PC patients. We analyzed 15 patients (median age: 66, range: 52-78 years) who underwent both 68Ga-PSMA and Al18F-PSMA PET/CT scanning within a time window of 1-2 weeks, 60 minutes after the i.v. administration of 2.0 and 4.0 MBq/kg, respectively. Studies were performed with a 64-slice PET/CT scan with TOF correction. Fourteen patients had high-risk biopsy proven PC prior therapy (Gleason > 7, PSA: 7.6-83 ng/mL). The remaining patient was imaged prior to 177Lu-PSMA therapy and had hormone-resistant metastatic disease (PSA: 21 ng/mL). The study was approved by the institutional Ethics Committee. We measured the SUVmax in all abnormal foci as well as the SUVmax ratio (SR) in all coincident lesions, defin...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Prostate Posters Source Type: research